LGVN logo

LGVN
Longeveron Inc - Ordinary Shares - Class A

12,955
Mkt Cap
$24.9M
Volume
1.2M
52W High
$1.83
52W Low
$0.475
PE Ratio
-0.82
LGVN Fundamentals
Price
$1.07
Prev Close
$1.12
Open
$1.11
50D MA
$0.698
Beta
1.02
Avg. Volume
14.62M
EPS (Annual)
-$1.29
P/B
4.32
Rev/Employee
$31,552.63
$5.06
Loading...
Loading...
News
all
press releases
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.
A Key 'Master' Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. A Key 'Master' Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. PR...
PR Newswire·18d ago
News Placeholder
More News
News Placeholder
Longeveron (LGVN) Q4 2025 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·18d ago
News Placeholder
Longeveron Braces For Q4 Results Following Recent Funding Boost
Longeveron Inc. shares are trading higher Tuesday as investors pivot their focus toward the company's Q4 earnings report, due after the bell.read more...
Benzinga·19d ago
News Placeholder
Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal
Longeveron shares are trading sharply higher Tuesday afternoon following the announcement of a private placement agreement worth up to $30 million.read more...
Benzinga·26d ago
News Placeholder
Best Biotech Stocks To Keep An Eye On - March 10th
Vertex Pharmaceuticals, BioNTech, Danaher, Longeveron, Moderna, United Therapeutics, and argenex are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...
MarketBeat·26d ago
News Placeholder
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study
Longeveron said that intravenous laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo.
Stocktwits·1mo ago
<
...
1
>

Latest LGVN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.